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Rivastigmine appeared to improve cognition compared with placebo in four separate studies, although meta-analysis was not performed (reasons unclear). 2164 participants; trial duration 14-52 weeks; most used a 12 mg dose. Memantine had no effect on cognition in mild to moderate Alzheimer's disease (1 RCT) but improved cognition in mild to moderate vascular dementia (2 RCTs). Trials of tacrine versus placebo used inconsistent assessments and gave inconsistent results, therefore no summary effect was calculated (total 1203 participants, trial duration 12-36 weeks; dose range from 80 to 160 mg).
CONCLUSIONS
Cholinesterase inhibitors, with the exception of tacrine, and memantine consistently improve most outcomes in people with dementia, particularly cognition and global functioning, but these improvements are clinically marginal. Meta-analysis is limited by inconsistencies in dementia classifications, the severity of the condition, assessment of outcomes, and reporting of adverse effects. (AChI) and Memantine aim at improving mainly outcomes in cognition, global function, behavior, and quality of life. The efficacy of these agents has been discussed intensively, taking into account the minimal benefits as measured by rating scales and the poor methodological quality of the underlying trials. [1] [2] [3] [4] In this systematic review Raina and colleagues try to focus on the effectiveness of AChI and Memantine, and address the important and pragmatic question of whether these drugs work in routine clinical care. Unfortunately, this extensive review does not teach us anything new. The results section is a meticulous description of 59 trials and their outcomes with summary estimates of effect sizes for the instruments of interest. Concerning the methodological quality of the trials under review, the authors mainly rely on the modified Jadad scale, although using quality scales and checklists is not recommended. Reflecting the controversy around the clinical evidence, the national regulations concerning prescription and treatment documentation differ strongly between countries. Generally, they tend towards an individualized approach: AChI and Memantine should be prescribed only after an individual consideration of potential benefits and harms, and effects should be monitored regularly and thoroughly.
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